JP2011529706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529706A5 JP2011529706A5 JP2011522168A JP2011522168A JP2011529706A5 JP 2011529706 A5 JP2011529706 A5 JP 2011529706A5 JP 2011522168 A JP2011522168 A JP 2011522168A JP 2011522168 A JP2011522168 A JP 2011522168A JP 2011529706 A5 JP2011529706 A5 JP 2011529706A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- mesenchymal stromal
- stromal cells
- cells
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002536 stromal cell Anatomy 0.000 claims description 45
- 239000006166 lysate Substances 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 230000001464 adherent effect Effects 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 claims description 2
- 102100037241 Endoglin Human genes 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 235000021110 pickles Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8603308P | 2008-08-04 | 2008-08-04 | |
| US61/086,033 | 2008-08-04 | ||
| PCT/US2009/052733 WO2010017216A2 (en) | 2008-08-04 | 2009-08-04 | Mesenchymal stromal cell populations and methods of isolating and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529706A JP2011529706A (ja) | 2011-12-15 |
| JP2011529706A5 true JP2011529706A5 (enExample) | 2012-09-20 |
Family
ID=41664170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522168A Pending JP2011529706A (ja) | 2008-08-04 | 2009-08-04 | 間充織間質細胞集団、ならびにそれを単離および使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110293576A1 (enExample) |
| EP (1) | EP2321408A4 (enExample) |
| JP (1) | JP2011529706A (enExample) |
| AU (1) | AU2009279736A1 (enExample) |
| CA (1) | CA2736353A1 (enExample) |
| WO (1) | WO2010017216A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010003057A2 (en) | 2008-07-03 | 2010-01-07 | Mayo Foundation For Medical Education And Research | Treating cancer |
| ES2982461T3 (es) | 2008-09-16 | 2024-10-16 | Mayo Found Medical Education & Res | Composiciones que contienen contenido plaquetario |
| WO2011053860A2 (en) * | 2009-10-30 | 2011-05-05 | Allocure, Inc. | Mesenchymal stromal cell populations and methods of using same |
| CN102639694B (zh) * | 2009-11-27 | 2015-05-27 | 斯蒂姆普优提克斯个人研究有限公司 | 制备间充质干细胞、组合物和其试剂盒的方法 |
| WO2011153205A1 (en) | 2010-06-01 | 2011-12-08 | Auxocell Laboratories, Inc. | Native wharton's jelly stem cells and their purification |
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| CA2840307C (en) | 2011-07-06 | 2021-10-19 | Cell Therapy Limited | Progenitor cells of mesodermal lineage |
| WO2013070765A1 (en) | 2011-11-09 | 2013-05-16 | Allocure, Inc. | Assay for the prediction of therapeutic effectiveness or potency of mesenchymal stem cells, and methods of using same |
| RS57886B1 (sr) * | 2011-11-30 | 2019-01-31 | Astellas Inst For Regenerative Medicine | Mezenhimalne stromalne ćelije i primene vezane za njih |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| WO2013166026A1 (en) | 2012-04-30 | 2013-11-07 | Allocure, Inc. | Methods of treating acute kidney injury using mesenchymal stem cells |
| CA2876499C (en) | 2012-07-12 | 2021-10-26 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| CA2917407C (en) | 2012-10-01 | 2023-03-14 | Mayo Foundation For Medical Education And Research | Complexes containing albumin-containing nanoparticles and antibodies to treat cancer |
| WO2014193895A1 (en) | 2013-05-29 | 2014-12-04 | Allocure, Inc. | Ex vivo perfusion of donor organs prior to transplantation using mesenchymal stem cells |
| ES2663482T3 (es) * | 2013-08-01 | 2018-04-12 | Fundación Pública Andaluza Progreso Y Salud | Método para predecir la respuesta al tratamiento y prueba para el uso seguro de células madre mesenquimatosas en enfermedades inflamatorias |
| US11891620B2 (en) | 2014-05-16 | 2024-02-06 | Mayo Foundation For Medical Education And Research | Cell culture media compositions for primary cells |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| JP6600651B2 (ja) | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| JP7525999B2 (ja) | 2016-09-01 | 2024-07-31 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| RU2756892C2 (ru) | 2016-09-06 | 2021-10-06 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| US20190060365A1 (en) * | 2017-08-25 | 2019-02-28 | Meridigen Biotech Co., Ltd. | Pharmaceutical composition for treating chronic obstructive pulmonary disease and method thereof |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
| EP3982724A1 (en) | 2019-06-11 | 2022-04-20 | Axogen Corporation | Wet preservation of tissue |
| JP7582958B2 (ja) * | 2019-09-30 | 2024-11-13 | テルモ株式会社 | 凍結保存細胞の希釈用緩衝液 |
| EP4190892A4 (en) * | 2020-07-31 | 2024-10-30 | Rainbow Inc. | Platelet lysate derived from autologous platelets |
| US20250075184A1 (en) | 2021-03-30 | 2025-03-06 | Kaneka Corporation | Method for inhibiting trypsin, and method for producing a cell preparation using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE528214C2 (sv) * | 2005-06-23 | 2006-09-26 | Proliff Ab | Förfarande för framställning av blodplättslysat |
| EP2069479A1 (en) * | 2006-09-18 | 2009-06-17 | Medizinische Universität Graz | Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics |
-
2009
- 2009-08-04 AU AU2009279736A patent/AU2009279736A1/en not_active Abandoned
- 2009-08-04 WO PCT/US2009/052733 patent/WO2010017216A2/en not_active Ceased
- 2009-08-04 JP JP2011522168A patent/JP2011529706A/ja active Pending
- 2009-08-04 US US13/057,698 patent/US20110293576A1/en not_active Abandoned
- 2009-08-04 EP EP09805454.7A patent/EP2321408A4/en not_active Withdrawn
- 2009-08-04 CA CA2736353A patent/CA2736353A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martin‐Rendon et al. | 5‐Azacytidine‐treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies | |
| Markarian et al. | Isolation of adipose-derived stem cells: a comparison among different methods | |
| JP7571109B2 (ja) | 改善された幹細胞組成物 | |
| Ishige et al. | Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord | |
| Kassis et al. | Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads | |
| Rebelatto et al. | Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue | |
| Haddad et al. | Mechanisms of T‐cell immunosuppression by mesenchymal stromal cells: What do we know so far? | |
| Wagner et al. | Mesenchymal stem cell preparations—comparing apples and oranges | |
| Lange et al. | High-potential human mesenchymal stem cells | |
| Bieback et al. | Clinical protocols for the isolation and expansion of mesenchymal stromal cells | |
| Najar et al. | Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources | |
| Lv et al. | Intrinsic properties of mesemchymal stem cells from human bone marrow, umbilical cord and umbilical cord blood comparing the different sources of MSC | |
| Jazayeri et al. | Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells | |
| Fazzina et al. | Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues | |
| Tran et al. | Various methods for isolation of multipotent human periodontal ligament cells for regenerative medicine: Tran et al. | |
| Dickhut et al. | Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue | |
| Jin et al. | GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells | |
| WO2013163959A1 (zh) | 用于分离培养干细胞的脂肪组织的长时间保存液 | |
| Yoshioka et al. | Isolation of mesenchymal stromal/stem cells from small-volume umbilical cord blood units that do not qualify for the banking system | |
| Jeschke et al. | Umbilical cord lining membrane and Wharton’s jelly-derived mesenchymal stem cells: the similarities and differences | |
| US12251402B2 (en) | Mesenchymal stem cells with enhanced immunosuppressive capability | |
| Kajimoto et al. | Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues | |
| Nakamura et al. | Culture medium study of human mesenchymal stem cells for practical use of tissue engineering and regenerative medicine | |
| Gaafar et al. | Comparative characteristics of endothelial-like cells derived from human adipose mesenchymal stem cells and umbilical cord blood-derived endothelial cells | |
| Wuchter et al. | Mesenchymal Stromal Cells (MSC) |